Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Thursday 28 July, 2011

AstraZeneca PLC

Second Quarter Results 2011 - Part 3 of 3

RNS Number : 2450L
AstraZeneca PLC
28 July 2011
 



AstraZeneca Development Pipeline

28 July 2011

 

Line Extensions

 

Compound

Mechanism

Area Under Investigation

Phase

Estimated Filing

US

EU

Japan

Emerging

Cardiovascular

Axanum

proton pump inhibitor + low dose aspirin FDC

low dose aspirin associated peptic ulcer

III

Withdrawn

Filed

2014

Filed

Brilinta PEGASUS-TIMI

ADP receptor antagonist

outcomes study

III

2014

2014

2014

2014

Crestor

statin

outcomes in subjects with elevated CRP

III

Launched

Launched

NA

Filed

Dapagliflozin/ metformin FDC#

SGLT2 inhibitor + metformin FDC

diabetes

III

2H 2012

2H 2012



Kombiglyze XR/ Onglyza/ metformin IR FDC#* 

DPP-4 inhibitor + metformin FDC

diabetes

III

Launched

Filed


Filed

Onglyza

SAVOR-TIMI#

DPP-4 inhibitor

outcomes study

III

2016




Gastrointestinal

Nexium

proton pump inhibitor

peptic ulcer bleeding

III

Filed**

Launched


Launched

Nexium

proton pump inhibitor

GERD

III

Launched

Launched

Approved

Launched

Neuroscience

Diprivan#

sedative and anaesthetic

conscious sedation

III


Launched

2H 2012

Launched

EMLA#

local anaesthetic

topical anaesthesia

III


Launched

Filed

Launched

Oncology

Faslodex

oestrogen receptor antagonist

high dose (500mg) 2nd line advanced breast cancer

III

Launched

Launched

Filed

Launched

Faslodex

oestrogen receptor antagonist

1st line advanced breast cancer

III

2016

2016

2016

2016

Iressa

EGFR tyrosine kinase inhibitor

1st line EGFR mut+ NSCLC

III


Launched

Filed

Launched

Iressa

EGFR tyrosine kinase inhibitor

treatment beyond progression

III


2015

2015

2015

Infection

FluMist/Fluenz

 

live, attenuated, intranasal influenza virus vaccine

influenza

III

Launched

Approved


Launched

Respiratory & Inflammation

Oxis

long-acting β2 agonist

COPD

III


Launched

3Q 2011


Symbicort

inhaled steroid/ long-acting β2 agonist

COPD

III

Launched

Launched

4Q 2011

Launched

Symbicort

inhaled steroid/ long-acting β2 agonist

SMART

III


Launched

3Q 2011

Launched

#Partnered product

*Kombiglyze XR US; Onglyza/metformin IR FDC EU

**(2nd) CRL Received

 

NCEs

Phase III/Registration

 

Compound

Mechanism

Area Under Investigation

Phase

Estimated Filing

US

EU

Japan

Emerging

Cardiovascular

Brilinta/Brilique

ADP receptor antagonist

arterial thrombosis

III

Approved

Launched

2013

Launched

Dapagliflozin#

SGLT2 inhibitor

diabetes

III

Filed

Filed

2013

Filed

Neuroscience

Vimovo#

naproxen + esomeprazole

signs and symptoms of OA, RA and AS

III

Launched

Launched


Launched

TC-5214#

neuronal nicotinic channel modulator

major depressive disorder (adjunct)

III

2H 2012

2015



NKTR-118#

oral peripherally-acting opioid antagonist

opioid-induced constipation

III

2013

2013



Oncology 

Caprelsa

(vandetanib)

VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity

medullary thyroid cancer

III

Launched

Filed

1H 2012

3Q 2011

Infection

MEDI-3250*

live, attenuated, intranasal influenza virus vaccine  (quadrivalent)

seasonal influenza

III

Filed

TBD



Zinforo# (ceftaroline)

extended spectrum cephalosporin with affinity to penicillin- binding proteins

pneumonia/skin infections

III


Filed


3Q 2011

Respiratory & Inflammation

Fostamatinib#

spleen tyrosine kinase (SYK) inhibitor

rheumatoid arthritis

III

2013

2013


2013

#Partnered product

*sBLA in US, MAA in EU

 

NCEs

Phases I and II

 

Compound

Mechanism

Area Under Investigation

Phase

Estimated Filing

US

EU

Japan

Emerging

Cardiovascular

AZD2820

melanocortin receptor type 4 (MC4r) partial agonist peptide

obesity

I





AZD2927

ion channel blocker/inhibitor

atrial fibrillation

I





AZD4017

11BHSD inhibitor

glaucoma

I





AZD7687

diacylglycerol acyl transferase -1 inhibitor

diabetes

I





AZD8329

11BHSD inhibitor

diabetes

I





CAT-354

anti-IL-13 MAb

ulcerative colitis

I





MEDI-2338

anti-IL-18 MAb

post ACS

I





Neuroscience

AZD2066

metabotropic glutamate receptor 5 antagonist

chronic neuropathic pain

II





AZD2423

 CCR2b antagonist

chronic neuropathic pain

II





AZD3480#

alpha4/beta2 neuronal nicotinic receptor agonist

Alzheimer's disease

II





AZD6765

NMDA receptor antagonist

major depressive disorder

II

2016

2016



TC-5214#

neuronal nicotinic channel modulator

major depressive disorder (monotherapy)

II





AZD1446#

alpha4/beta2 neuronal nicotinic receptor agonist 

Alzheimer's disease

I





AZD3241

myeloperoxidase (MPO) inhibitor

Parkinson's disease

I





AZD3839#

beta-secretase (BACE) inhibitor

Alzheimer's disease

I





AZD5213

H3AN

Alzheimer's disease/ADHD

I





MEDI-578

anti-NGF MAb

OA pain

I





#Partnered product

 

NCEs

Phases I and II (continued)

 

Compound

Mechanism

Area Under Investigation

Phase

Estimated Filing

US

EU

Japan

Emerging

Oncology

AZD1152

Aurora kinase inhibitor

haematological malignancies

II





AZD8931

erbB kinase inhibitor

breast cancer chemo combi/solid tumours

II

2015

2015



MEDI-575#

anti-PDGFR-alpha mAb

solid tumours

II





Olaparib

PARP inhibitor

serous ovarian cancer

II

2015

2015

2015

2015

Selumetinib# (AZD6244)

(ARRY-142886)

MEK inhibitor

solid tumours

II

2015

2015



AZD1480

JAK1, 2 inhibitor

solid tumours with options in myeloproliferative diseases

I





AZD2014

 TOR kinase inhibitor

solid tumours

I





AZD3514

androgen receptor downregulator

prostate cancer

I





AZD4547

FGFR tyrosine kinase inhibitor

solid tumours

I





AZD5363

AKT inhibitor

solid tumours

I





AZD8330#

(ARRY 424704)

MEK inhibitor

solid tumours

I





Selumetinib (AZD6244)  (ARRY-142886)

/MK2206#

MEK/AKT inhibitor

solid tumours

I





CAT-8015

anti-CD22 recombinant immunotoxin

haematological malignancies

I





MEDI-551

anti-CD19 MAb

haematological malignancies

I





MEDI-565

 anti-CEA BiTE

solid tumours

I





MEDI-573#

anti-IGF MAb

solid tumours

I





MEDI-3617#

 anti-ANG-2 MAb

solid tumours

I





Infection

AZD9773#

anti-TNF-alpha polyclonal antibody

severe sepsis

II

2015

2015

2015

2015

CAZ104#

beta lactamase inhibitor/

cephalosporin

serious infections

II

NA

2014

2014

2014

CXL104# (CEF104)

beta lactamase inhibitor/

cephalosporin

MRSA

II

NA

2015


2015

AZD5099

Gyrase B

serious infections

I





AZD5847

oxazolidinone antibacterial inhibitor

tuberculosis

I





MEDI-534

 

RSV/PIV-3 vaccine

RSV/PIV prophylaxis

I





MEDI-550

pandemic influenza virus vaccine

pandemic influenza prophylaxis

I





MEDI-557

 

RSV MAb - extended half-life

RSV prevention in high-risk adults (COPD/CHF/

Other)

I





MEDI-559

RSV vaccine

RSV prophylaxis

I





#Partnered product

 

NCEs

Phases I and II (continued)

 

Compound

Mechanism

Area Under Investigation

Phase

Estimated Filing

US

EU

Japan

Emerging

Respiratory & Inflammation

AZD1981

CRTh2 receptor antagonist

asthma/COPD

II





AZD2423

CCR2b antagonist

COPD

II





AZD3199

iLABA

asthma/COPD

II





AZD5069

CXCR2

COPD

II





AZD5423

inhaled SEGRA

COPD

II





AZD8848

Toll like receptor 7 agonist

asthma

II





CAM-3001#

anti-GM-CSFR MAb

rheumatoid arthritis

II





CAT-354

anti-IL-13 MAb

asthma

II





MEDI-528#

anti-IL-9 MAb

asthma

II





MEDI-545#

anti-IFN-alpha MAb

SLE

II





MEDI-563#

anti-IL-5R MAb

asthma

II





AZD2115

MABA

COPD

I





AZD8683

muscarinic antagonist

COPD

I





MEDI-546#

anti-IFN-alphaR MAb

scleroderma

I





MEDI-551

anti-CD19 MAb

scleroderma

I





MEDI-570#

anti-ICOS MAb

SLE

I





MEDI-2338

anti-IL-18 MAb

COPD

I





MEDI-8968#

anti-IL-1R

COPD

I





#Partnered product

 

Development Pipeline - Discontinued Projects vs 27 January 2011

 

Cardiovascular/Gastrointestinal

NCE/Line Extension

Compound

Area Under Investigation

NCE

AZD1656

diabetes

NCE

AZD5658

diabetes

NCE

AZD6714

diabetes

 

Neuroscience

NCE/Line Extension

Compound

Area Under Investigation

NCE

AZD2066

major depressive disorder

NCE

AZD3043

short acting sedative/anaesthetic

NCE

TC-5619

cognitive disorders in schizophrenia

 

Oncology

NCE/Line Extension

Compound

Area Under Investigation

NCE

AZD2461

solid tumours

NCE

AZD7762

solid tumours

NCE

AZD8055

range of tumours

NCE

RECENTIN

NSCLC

NCE

Zibotentan

castrate resistant prostate cancer

 

Infection

NCE/Line Extension

Compound

Area Under Investigation

NCE

AZD9742

MRSA

NCE

Motavizumab

early and late treatment of RSV in paeds >1 yr

 

Respiratory & Inflammation

NCE/Line Extension

Compound

Area Under Investigation

NCE

AZD9819

COPD

 

Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

 

Compounds in development are displayed by phase.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR GUGDRGDDBGBI

a d v e r t i s e m e n t